ThirtyFiveBio Ltd
- Biotech or pharma, therapeutic R&D
ThirtyFiveBio are developing GPR35 inhibitors for the treatment of ulcerative colitis. GPR35 inhibition protects the gut epithelium from inflammatory damage and as such provides and anti-inflammatory-orthogonal approach that promises to break the response ceiling in this population of patients.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}